NHLBI’s AsthmaNet Clinical Trial Results 2018
Saturday, March 3, 2018: 10:45 AM-12:00 PM
Convention Center, South Concourse, Level 3, S330GH
1.25 CME/CE
Primary Moderators:
William W. Busse, MD FAAAAI
James P. Kiley, PhD

Learning Objectives:
  1. Identify the preferred step-up therapy in African Americans ages 5 and older with asthma who are inadequately controlled on low dose ICS and the degree to which African ancestry affects preference for different therapies
  2. Discuss whether or not increasing from low to high dose ICS in the "yellow zone" reduces risk of severe asthma exacerbations
  3. Discuss the evidence linking the airway microbiome composition and the response to inhaled corticosteroids
10:45 AM
Best African American Response to Asthma Drugs: The NHLBI BARD Trial
Michael E. Wechsler, MD MMSc
11:05 AM
Question & Answer
11:10 AM
Does Increasing ICS in the “Yellow Zone” Prevent Severe Asthma Exacerbations in School Age Children?
Daniel J. Jackson, MD FAAAAI
11:30 AM
Question & Answer
11:35 AM
Is the Airway Microbiome Associated with a Risk of Asthma Exacerbations in Children?
Avraham Beigelman, MD MSCI FAAAAI
Recipient of the Robert G. Townley Memorial Lectureship: 4th year
11:55 AM
Question & Answer
See more of: Session